Processa Pharmaceuticals Announces Successful Phase 2 Meeting with FDA for Next Generation Capecitabine
13. Dezember 2023 09:00 ET
|
Processa Pharmaceuticals, Inc.
FDA provides guidance on Phase 2 design and Processa to continue with pre-study activities for Phase 2 trial HANOVER, MD, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq:...